CASI Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David A. Cory
- Full Time Employees
- 214
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1701-1702, China Central Office Tower 1 Beijing BE People's Republic of China 100025
- IPO Date
- Jun 12, 1996
- CIK
- 0001962738
- Website
- casipharmaceuticals.com
- Similar Companies
- Business
- CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company engages in acquiring, developing, and commercializing hematology and oncology medicines and related products, with an emphasis on introducing therapies via its China-based regulatory and commercial capabilities and its global drug development expertise. Headquartered in Rockville, Maryland, CASI operates primarily through its Beijing-based subsidiary CASI Pharmaceuticals (China) Co., Ltd., which supports regulatory, commercial, and clinical activities in Greater China. Founded in 2000, the company’s principal products and services include EVOMELA (intravenous melphalan) for conditioning prior to autologous stem cell transplantation and palliative care in multiple myeloma, CNCT19 (autologous CD19 CAR-T) in development, and a pipeline that encompasses CID-103 (anti-CD38 monoclonal antibody) and other hematology/oncology candidates; in addition, CASI pursues acquisitions, strategic partnerships, and licensing arrangements to broaden its portfolio and geographic reach. The company’s geographic footprint covers the United States, China, and international markets, with a commercial focus in China through its subsidiary and a broader global development and commercialization strategy. CASI collaborates with partners and engages in strategic alliances, funding activities, and product launches to expand its offerings and market presence, alongside ongoing development of its hematology and oncology assets and related technologies.
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Announces Changes in Board Governance
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Appoints James Huang to Board of Directors
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
CASI Pharmaceuticals Provides Business and Clinical Update